Bacanora Minerals is an AIM and TSX listed company focused on becoming a large scale supplier to the fast growing global lithium-ion battery market. Thanks to soaring demand from cutting edge industries such as electric vehicles and energy storage, demand for battery grade lithium is forecast to grow strongly in the short to medium term which is expected to drive the market up from $17.5 billion to $70 billion by 2020. With this in mind, the Company is rapidly commercialising the world class Sonora Lithium Project in Mexico which benefits from a large, scalable and high grade lithium resource NI 43-101 Indicated Resource. A PFS has been completed which highlight the attractive economics of producing up to 35,000 tonnes per annum of battery grade Li2CO3 at Sonora and estimates a pre-tax Internal Rate of Return ('IRR') of 29% (post tax 25%) and an associated Net Present Value ('NPV') of US$776M, (8% discount rate). CAD$13.7 million has been invested to date both on exploration and on the development of a pilot plant in nearby Hermosillo. The Company owns the Magdalena Borate Project, also in Mexico, which has the potential to provide near term cash flow to the Company as it advances its lithium asset.

Company Website

Financial Calendar

Recent Broker notes

BarChart Indicators

Recent Market news

BCN's Fundamentals (BCN)

Tuesday 29th November 2016

Novotel Tower Bridge, London EC3N, 10 Pepys Street, London, EC3N 2NR

Bacanora Minerals (BCN)

Bacanora Minerals Ltd  is an explorer and developer of industrial minerals in Mexico with a primary focus on Borates and Llithium. It was incorporated in Alberta, Canada in September 2008 and is listed on the TSX Venture Exchange (ticker = BCN). Although listed in Canada, we are proud to consider ourselves a Mexican Company. The word Bacanora refers to a Mexican agave liquor traditionally distilled in the hills of Sonora with much care and attention. Bacanora Minerals strives to replicate this tradition of skill and dedication to quality in its own operations.

Kennedy Ventures (KENV)

Kennedy Ventures plc is an investing company listed on AIM, focused on principally, but not exclusively, in the resources sector. The Company has made a first investment in African Tantalum (Pty) Ltd, a Namibian based operation producing tantalite concentrate. In view of the attractive opportunities in tantalum, the Company is likely to initially focus on related projects located in Southern Africa.

Valirx (VAL)

Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs. Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers. The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow. A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation.